Blueprint Medicines
Stock Forecast, Prediction & Price Target
Blueprint Medicines (BPMC) stock Price Target by analysts
$126
Potential downside: -2.67%
Blueprint Medicines price prediction
What is Blueprint Medicines stock analysts` prediction?
Blueprint Medicines stock forecast: Based on 3 Wall Street analysts` predicted price targets for Blueprint Medicines in the last 3 months, the avarage price target is $126, with a high forecast of $NaN. The average price target represents a -2.67% change from the last price of $129.46.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Blueprint Medicines stock Price Target by analysts
Full breakdown of analysts given Blueprint Medicines price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Ami Fadia Needham | 0% 0/1 | 10 months ago | $135 4.27% upside | $89.24 | StreetInsider | Previous targets (0) |
David Dai UBS | 0% 0/1 | 11 months ago | $88 -32.02% downside | $84.4 | StreetInsider | Previous targets (0) |
Bradley Canino Stifel Nicolaus | 0% 0/1 | 12 months ago | $155 19.72% upside | $90.94 | StreetInsider | Previous targets (0) |
Matthew Biegler Oppenheimer | 33.33% 1/3 | about 1 year ago | $130 0.41% upside | $102.05 | TheFly | Previous targets (2) |
Peter Lawson Barclays | 0% 0/1 | about 1 year ago | $105 -18.89% downside | $112.19 | TheFly | Previous targets (0) |
Matthew Biegler Oppenheimer | 33.33% 1/3 | about 1 year ago | $125 -3.44% downside | $116.55 | StreetInsider | Previous targets (2) |
Andrew Berens Leerink Partners | 0% 0/1 | over 1 year ago | $97 -25.07% downside | $107.19 | StreetInsider | Previous targets (0) |
Andrew Fein H.C. Wainwright | 50% 1/2 | over 1 year ago | $135 4.27% upside | $107 | TheFly | Previous targets (1) |
Christopher Raymond Raymond James | 0% 0/1 | over 1 year ago | $104 -19.66% downside | $106.29 | StreetInsider | Previous targets (0) |
Unknown Needham | N/A | over 2 years ago | $60 -53.65% downside | $46.6 | Benzinga | N/A |
Andrew Fein H.C. Wainwright | 50% 1/2 | almost 3 years ago | $70 -45.92% downside | $46.1 | TipRanks Contributor | Previous targets (1) |
Matthew Biegler Oppenheimer | 33.33% 1/3 | about 3 years ago | $90 -30.48% downside | $70.66 | TheFly | Previous targets (2) |
Derek Archila Wells Fargo | 100% 1/1 | about 3 years ago | $41 -68.32% downside | $52.78 | TheFly | Previous targets (0) |
Christopher Raymond Piper Sandler | 100% 1/1 | over 3 years ago | $65 -49.79% downside | $55.5 | TheFly | Previous targets (0) |
Michael Ulz Morgan Stanley | 100% 1/1 | over 3 years ago | $92 -28.93% downside | $79.16 | TipRanks Contributor | Previous targets (0) |
Michael Schmidt Guggenheim | 0% 0/1 | over 3 years ago | $122 -5.76% downside | $110.08 | TheFly | Previous targets (0) |
Dane Leone Raymond James | 0% 0/1 | almost 4 years ago | $133 2.73% upside | $114.95 | StreetInsider | Previous targets (0) |
Salveen Richter Goldman Sachs | 0% 0/1 | about 4 years ago | $147 13.54% upside | $84.74 | StreetInsider | Previous targets (0) |
Arlinda Lee Canaccord Genuity | 0% 0/1 | about 4 years ago | $120 -7.30% downside | $83.53 | TipRanks | Previous targets (0) |
Blueprint Medicines Financial Estimates
Blueprint Medicines Revenue Estimates
Blueprint Medicines EBITDA Estimates
Blueprint Medicines Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $180.08M N/A | $204.03M 13.30% | $249.38M 22.22% | Avg: $648.16M Low: $578.91M High: $953.66M avg. 159.91% | Avg: $886.99M Low: $796.51M High: $1.19B avg. 36.84% | Avg: $1.14B Low: $1.03B High: $1.54B avg. 29.51% | Avg: $1.29B Low: $1.16B High: $1.74B avg. 12.80% |
Net Income
% change YoY
| $-644.08M N/A | $-557.51M 13.44% | $-506.98M 9.06% | Avg: $-120.25M Low: $-241.02M High: $103.55M avg. 76.27% | Avg: $61.86M Low: $-150.18M High: $355.47M avg. 151.44% | Avg: $276.29M Low: $239.65M High: $400.68M avg. 346.62% | Avg: $391.58M Low: $339.65M High: $567.87M avg. 41.72% |
EBITDA
% change YoY
| $-641.98M N/A | $-537.51M 16.27% | $-470.35M 12.49% | Avg: $-468.11M Low: $-688.75M High: $-418.10M avg. 0.47% | Avg: $-640.60M Low: $-862.44M High: $-575.25M avg. -36.84% | Avg: $-829.64M Low: $-1.11B High: $-745.01M avg. -29.51% | Avg: $-935.86M Low: $-1.25B High: $-840.39M avg. -12.80% |
EPS
% change YoY
| -$11.01 N/A | -$9.35 15.07% | -$8.37 10.48% | Avg: -$1.39 Low: -$3.98 High: $1.71 avg. 83.45% | Avg: $1.62 Low: -$2.48 High: $5.87 avg. 216.70% | Avg: $4.56 Low: $3.96 High: $6.62 avg. 182.24% | Avg: $6.47 Low: $5.61 High: $9.38 avg. 41.72% |
Operating Expenses
% change YoY
| $804.12M N/A | $723.74M -9.99% | $722.86M -0.12% | Avg: $658.44M Low: $588.09M High: $968.79M avg. -8.91% | Avg: $901.06M Low: $809.14M High: $1.21B avg. 36.84% | Avg: $1.16B Low: $1.04B High: $1.57B avg. 29.51% | Avg: $1.31B Low: $1.18B High: $1.77B avg. 12.80% |
FAQ
What is Blueprint Medicines stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 154.01% in 2025-2028.
We have gathered data from 13 analysts. Their low estimate is -241.02M, average is -120.25M and high is 103.55M.
What is Blueprint Medicines stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 59.76% in 2025-2028.
We have gathered data from 14 analysts. Their low revenue estimate is $578.91M, average is $648.16M and high is $953.66M.
What is Blueprint Medicines stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 131.03% in 2025-2028.
We have gathered data from 13 analysts. Their low earnings per share estimate is -$3.98, average is -$1.39 and high is $1.71.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Blueprint Medicines stock. The most successful analyst is Ami Fadia.